⚠ Evidence warning: Clinical trials or other evidence do not support the claims that the low-density lipoprotein effect of cinnamon is clinically relevant and can bring borderline values to the treatment target, that a washout showed continued intake is needed to keep the lipid effect, that the lipid signal persisted across most follow-up trials, that later trials showed up to about a 15% low-density lipoprotein reduction, and that cinnamon may give a clinically meaningful reduction in borderline elevations. This page keeps it as a report of what people, websites or other media say.

Cinnamon for Cardiovascular Health

The cardiovascular effects of cinnamon rode in on the coattails of the diabetes trials. Khan et al. 2003, designed to measure glucose, reported that low-density lipoprotein (LDL) cholesterol dropped 7–27% and triglycerides dropped 23–30% across the three cinnamon dose arms. In 2025 the journal that published it issued an expression of concern: independent statisticians found problems with its randomization, its reported standard deviations and its unusually high adherence, which question whether the reported data are plausible. The Maierean 2017 systematic review and meta-analysis of 13 randomized controlled trials (RCTs) (750 participants) found a statistically significant reduction in triglycerides and total cholesterol, and no significant effect on low-density lipoprotein or high-density lipoprotein (HDL). Beyond lipids, cinnamaldehyde has documented anti-platelet aggregation activity (thromboxane A2 inhibition) and a modest blood-pressure-lowering effect reported in type 2 diabetic patients (Akilen 2010). This page walks through the lipid trials, the blood-pressure effect, the anti-platelet mechanism, and where the trial populations overlap with cardiovascular risk.


Table of Contents

  1. The Khan 2003 Lipid Findings
  2. The Maierean 2017 Lipid Meta-Analysis
  3. Triglyceride Reduction Mechanism
  4. Low-Density Lipoprotein Cholesterol Effects
  5. Blood Pressure: The Akilen 2010 Trial
  6. Anti-Platelet Effect: Thromboxane A2 Inhibition
  7. Endothelial Function and Nitric Oxide
  8. Oxidized Low-Density Lipoprotein and Atherosclerosis
  9. Clinical Doses for Lipid Reduction
  10. Where the Trial Populations Overlap With Cardiovascular Risk
  11. Drug Interactions and Cautions
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Khan 2003 Lipid Findings

The lipid results from Khan et al. 2003 (covered in detail on our blood-sugar page) were arguably as striking as the glucose results. The trial reported that its 60 Pakistani type 2 diabetic patients, randomized to 1, 3, or 6 g/day of cinnamon or matching placebo capsules for 40 days, showed:

Expression of concern (2025). These figures are not established. In September 2025 the American Diabetes Association, publisher of Diabetes Care, issued an expression of concern on the Khan 2003 paper. Independent statisticians it commissioned found significant differences between the study groups at the start (which proper randomization is not expected to produce), an unclear description of how people were randomized and whether they were blinded, unusually low variability with possible mix-ups of standard deviations and standard errors, no formal test of the dose–response the study set out to measure, and unusually high adherence with no one lost to follow-up. The journal could not reach the authors to obtain the underlying data, and it states that these issues concern the plausibility of the data reported (Diabetes Care 2025, PubMed PMID: 40834253).

The magnitude of triglyceride reduction is particularly notable. A 30% triglyceride reduction, if real, would be in the same range as fibrate therapy (gemfibrozil typically reduces triglycerides 20–50%) and larger than statin monotherapy typically achieves on triglycerides. For a patient with metabolic syndrome and the atherogenic dyslipidemia pattern (high triglycerides, low high-density lipoprotein, small dense low-density lipoprotein particles), such an effect would be meaningful. The low-density lipoprotein effect was smaller in absolute terms but still clinically relevant — in patients with baseline low-density lipoprotein of 130–160 mg/dL, a 7–27% reduction brings the value into or below the standard treatment target.

The trial also included a 20-day washout period after the 40 days of cinnamon. As with the glucose results, the 20-day washout showed partial reversal, confirming that continued intake is needed to maintain the effect.

The Khan results were greeted with skepticism from the start — effect sizes in a small single-country cohort tend to shrink when replicated in larger and more diverse populations. The lipid signal has persisted across most follow-up trials, even when the glucose signal has been weaker. Later pooled analyses found smaller lipid effects. A 2025 meta-analysis of 28 randomized trials (3,054 people with type 2 diabetes, 30 to 120 days) found that cinnamon in capsule form lowered total cholesterol by about 13.4 mg/dL, low-density lipoprotein by about 6.5 mg/dL and triglycerides by about 19.8 mg/dL compared with control, with large differences between trials (de Moura 2025). The Maierean 2017 meta-analysis (below) found lower triglycerides and total cholesterol but no significant change in low-density lipoprotein.

Back to Table of Contents

The Maierean 2017 Lipid Meta-Analysis

The most comprehensive synthesis of cinnamon's lipid effects is Maierean et al. 2017 in the Journal of Clinical Lipidology. The authors performed a systematic review and random-effects meta-analysis of 13 randomized controlled trials (750 participants) that reported lipid endpoints in cinnamon-vs-placebo or cinnamon-vs-control comparisons.

Pooled effects:

The triglyceride effect is the most robust finding across trials. The low-density lipoprotein change did not reach statistical significance and is small in absolute terms — far smaller than statin therapy (which typically reduces low-density lipoprotein 30–55% depending on intensity). The high-density lipoprotein effect is essentially noise-level positive. The authors found no link between the size of the lipid changes and the cinnamon dose, but longer supplementation was linked to larger changes in total cholesterol, low-density lipoprotein and triglycerides.

A larger 2025 meta-analysis of 49 studies, assessed with the GRADE system, reported that cinnamon lowered low-density lipoprotein cholesterol, total cholesterol, triglycerides, systolic and diastolic blood pressure and C-reactive protein (CRP), and raised high-density lipoprotein cholesterol. It gave its results as standardized effect sizes rather than in mg/dL (Jafari 2025). Unlike Maierean 2017, it found changes in low-density and high-density lipoprotein; the two analyses differ in the studies they included and in their methods.

Subgroup analysis suggested the effect was larger in patients with diabetes or metabolic syndrome than in patients with isolated dyslipidemia and normal glucose tolerance. This fits the mechanism — the insulin-sensitization pathway that produces glucose lowering also reduces hepatic very-low-density lipoprotein (VLDL) output and lipogenesis, which is the most plausible mechanism behind the triglyceride reduction.

Back to Table of Contents

Triglyceride Reduction Mechanism

The triglyceride-lowering effect of cinnamon is mechanistically linked to its insulin-sensitization effect. In insulin-resistant patients, the liver overproduces very-low-density lipoprotein (VLDL) particles, which are triglyceride-rich and are the precursors of small dense low-density lipoprotein. The drivers of very-low-density lipoprotein overproduction in insulin resistance are:

  1. Increased free fatty acid delivery to the liver. Adipose tissue under insulin resistance fails to suppress lipolysis appropriately, dumping free fatty acids into portal circulation. The liver re-esterifies these to triglycerides and packages them into very-low-density lipoprotein.
  2. Increased hepatic de novo lipogenesis. Sterol regulatory element-binding protein 1c (SREBP-1c), the master transcription factor for lipogenic enzymes (acetyl-CoA carboxylase, fatty acid synthase), is upregulated by insulin signaling — but in selective hepatic insulin resistance, this pathway remains insulin-responsive even when glucose uptake is impaired. Net effect: more triglyceride synthesis from glucose.
  3. Reduced LPL (lipoprotein lipase) clearance. Adipose-tissue LPL, which clears triglyceride-rich lipoproteins from circulation, is also impaired in insulin resistance.

Cinnamaldehyde and methylhydroxychalcone polymer (MHCP), by improving insulin sensitization in skeletal muscle and adipose tissue, reduce the free-fatty-acid spillover to the liver, reduce hepatic SREBP-1c-driven lipogenesis, and indirectly improve LPL-mediated clearance. In the pooled trials, triglycerides fell by 23.91 mg/dL (Maierean 2017) and by 19.75 mg/dL with capsule cinnamon in type 2 diabetes (de Moura 2025); the larger 20–30% figure comes from the Khan 2003 trial, which carries a 2025 expression of concern. The mechanism is consistent with the observation that the triglyceride effect is larger in insulin-resistant patients than in patients with isolated familial dyslipidemia (where the pathway is genetic and not insulin-mediated).

For patients interested in the broader topic of insulin resistance and triglycerides, see our metabolic syndrome page.

Back to Table of Contents

Low-Density Lipoprotein Cholesterol Effects

The low-density lipoprotein effects of cinnamon are smaller and less consistent than the triglyceride effects. The Khan 2003 trial reported a 7–27% low-density lipoprotein reduction, but that paper carries a 2025 expression of concern questioning the plausibility of its data. Subsequent trials have produced a wider range from null to ~15% reduction. The Maierean 2017 meta-analysis pooled estimate is −6.19 mg/dL and not statistically significant; the 2025 de Moura meta-analysis found about −6.5 mg/dL for capsule cinnamon in type 2 diabetes. Both are small in clinical terms.

The mechanism is likely twofold: (1) the triglyceride reduction reduces very-low-density lipoprotein output, which secondarily reduces the low-density lipoprotein precursor pool, and (2) cinnamaldehyde inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity in hepatocyte cell culture, suggesting a direct cholesterol-synthesis-inhibition effect similar to (but much weaker than) the statin mechanism. The HMG-CoA reductase inhibition is concentration-dependent in vitro and has not been definitively confirmed at clinically achievable plasma cinnamaldehyde concentrations in humans.

In practical terms, the research does not show cinnamon lowering low-density lipoprotein anywhere near as much as statin therapy: the pooled effect is at best a tenth of moderate-intensity statin therapy. For people with borderline low-density lipoprotein elevations, the pooled trials point to at most a small additional reduction. For patients with borderline low-density lipoprotein elevations who do not yet meet treatment criteria, cinnamon may produce a clinically meaningful but small additional reduction as part of a lifestyle-and-supplement stack.

Back to Table of Contents

Blood Pressure: The Akilen 2010 Trial

Cinnamon's blood-pressure effect was demonstrated most clearly in Akilen et al. 2010 in Diabetic Medicine — a 12-week randomized trial of 2 g/day of cassia cinnamon vs placebo in 58 type 2 diabetic patients (25 men and 33 women, mean age 54.9) with hemoglobin A1c (HbA1c) >7% in the UK, treated only with glucose-lowering drugs. Results:

The blood-pressure effect was modest in absolute terms but consistent and statistically significant. A 5 mmHg diastolic reduction is in the range of low-dose angiotensin-converting enzyme inhibitor (ACE inhibitor) or thiazide diuretic therapy and has been associated in meta-analysis with a 20% reduction in stroke incidence over 5 years if sustained.

A 2020 meta-analysis (Hadi et al. 2020) pooled 9 randomized controlled trials of cinnamon and blood pressure (641 participants) and found systolic pressure lower by 5.17 mmHg (95% confidence interval −9.35 to −0.99) and diastolic pressure lower by 3.36 mmHg (−5.67 to −1.04). In its subgroup analyses the reductions were significant only at doses of 2 g/day or less, for longer than 8 weeks, and in people with a baseline body mass index of 30 kg/m² or more.

A 2024 umbrella review that brought together the earlier meta-analyses found smaller blood-pressure effects than the single trials: systolic −2.36 mmHg and diastolic −1.65 mmHg. Total antioxidant capacity rose and interleukin-6 (IL-6) fell, while C-reactive protein, malondialdehyde (a marker of fat oxidation) and intercellular adhesion molecule 1 (ICAM-1) did not change significantly. The authors note the limited number of studies (Zhang 2024).

The mechanism is plausibly multifactorial: (1) improved insulin sensitization reduces sympathetic nervous system tone (insulin resistance is associated with elevated sympathetic outflow), (2) cinnamaldehyde has direct vasodilator activity in isolated vessel preparations, possibly through nitric oxide pathway, and (3) the modest weight-loss and metabolic improvements indirectly lower blood pressure (a 2020 meta-analysis of 12 trials with 786 people found body weight 1.02 kg and body mass index 0.51 kg/m² lower with cinnamon; Mousavi 2020). The 5 mmHg effect is unlikely to replace antihypertensive medication in patients with stage 2 hypertension but may meaningfully contribute in patients with prehypertension or stage 1 hypertension who are already on lifestyle modification. For more on hypertension management, see our hypertension page.

Back to Table of Contents

Anti-Platelet Effect: Thromboxane A2 Inhibition

Cinnamaldehyde inhibits platelet aggregation through thromboxane A2 pathway interference — the same pharmacologic target as aspirin, though through a different molecular mechanism. Aspirin irreversibly acetylates cyclooxygenase (cyclooxygenase-1, COX-1) in platelets, preventing thromboxane A2 synthesis. Cinnamaldehyde appears to inhibit thromboxane synthesis through a different mechanism (possibly inhibition of thromboxane synthase or reduction of arachidonic acid release), but the downstream effect — reduced platelet aggregation in response to collagen, adenosine diphosphate (ADP), or thromboxane analog — is similar.

A 2010 laboratory study tested 13 compounds isolated from cassia cinnamon in the test tube. Cinnamaldehyde, coumarin, cinnamic acid and two other compounds inhibited platelet clumping triggered by U46619 (a thromboxane A2 mimic) 2.5 to 4 times more strongly than aspirin; eugenol and coniferaldehyde were the most active anti-platelet compounds, and the compounds had little or no effect on blood clotting (Kim 2010).

The clinical significance is uncertain at culinary doses. In vitro and animal studies show measurable anti-aggregation effects at micromolar cinnamaldehyde concentrations. In humans, supplemental cinnamon doses (1–6 g/day) produce small reductions in platelet aggregation assays, but no published trials have measured clinically relevant cardiovascular endpoints (myocardial infarction, stroke) attributable to cinnamon's anti-platelet effect.

The practical implications:

Back to Table of Contents

Endothelial Function and Nitric Oxide

Endothelial dysfunction — the failure of vascular endothelium to produce adequate nitric oxide in response to shear stress and acetylcholine — is one of the earliest detectable abnormalities in patients with insulin resistance, type 2 diabetes, hypertension, and atherosclerosis. It precedes overt atherosclerotic plaque formation by years to decades and is a marker for future cardiovascular events.

Laboratory work points to two ways cinnamon could act on the endothelium: (1) cinnamaldehyde directly stimulates endothelial nitric oxide synthase (eNOS) activity in isolated vessel preparations, increasing local nitric oxide bioavailability, and (2) the procyanidin polyphenols in cinnamon have antioxidant activity that protects against oxidative inactivation of nitric oxide by superoxide radicals.

Human trial evidence is thin. In a 2016 randomized trial, 204 people with type 2 diabetes took 3 g of cinnamon, 3 g of cardamom, 1 g of saffron or 3 g of ginger with three glasses of black tea a day, or the tea alone, for 8 weeks; blood pressure and soluble intercellular adhesion molecule 1 (a blood marker of endothelial function) did not differ significantly between the groups (Azimi 2016). Effects in patients with established cardiovascular disease have been less studied. Whether any effect on the endothelium translates to fewer cardiovascular events is unproven.

Back to Table of Contents

Oxidized Low-Density Lipoprotein and Atherosclerosis

The atherosclerotic process begins not with high low-density lipoprotein per se but with low-density lipoprotein particles becoming oxidized in the subendothelial space, where they trigger inflammatory macrophage recruitment and foam cell formation. Antioxidant defense at the low-density lipoprotein-particle level is a meaningful determinant of atherosclerotic progression.

Cinnamon's type-A procyanidins and cinnamaldehyde both have measurable antioxidant capacity in standard assays (oxygen radical absorbance capacity (ORAC), Trolox equivalent antioxidant capacity (TEAC), ferric reducing antioxidant power (FRAP)). The clinical relevance is harder to establish — the systemic antioxidant capacity of supplemented adults rises modestly with cinnamon intake but has not been linked to a quantified reduction in cardiovascular events. The Beta-Carotene and Retinol Efficacy Trial (CARET) and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study taught the field that antioxidant supplementation does not always translate to cardiovascular benefit, particularly for isolated high-dose antioxidants.

The reasonable framing: cinnamon's antioxidant contribution is one of many small effects, not a stand-alone cardiovascular intervention. Dietary pattern (Mediterranean diet, high fruit and vegetable intake) remains the dominant determinant of antioxidant exposure, with cinnamon contributing at the margin.

Back to Table of Contents

Clinical Doses for Lipid Reduction

The dose range for lipid-modifying effects parallels the glycemic-effect dose range: 1–6 g/day of whole-spice cassia, or polyphenol-equivalent aqueous extract. The Khan 2003 trial reported similar lipid effects across the three dose arms (1, 3, 6 g/day), but it ran no formal dose–response test and carries a 2025 expression of concern. The Maierean 2017 meta-analysis found no significant link between cinnamon dose and lipid changes, and the de Moura 2025 meta-analysis found that only doses of 2 g/day or less lowered HbA1c.

Amounts described for cardiovascular adjunct use:

The Maierean 2017 meta-analysis found that longer supplementation was linked to larger changes in total cholesterol, low-density lipoprotein and triglycerides, and the 28 trials in the de Moura 2025 meta-analysis lasted 30 to 120 days. Triglyceride changes appear earliest; low-density lipoprotein changes more gradual.

Back to Table of Contents

Where the Trial Populations Overlap With Cardiovascular Risk

The cinnamon trials enrolled mostly people with type 2 diabetes, prediabetes or excess weight. These are the groups whose cardiovascular risk overlaps with what the trials measured:

The trials above compared cinnamon with placebo or no cinnamon; none compared it with these proven cardiovascular therapies:

On these trial numbers, cinnamon sits among several low-cost additions (alongside fish oil for triglycerides, magnesium for blood pressure, fiber for lipids) whose effects are modest next to the main factors of diet, exercise, weight loss and, when used, drug therapy.

Back to Table of Contents

Drug Interactions and Cautions

Back to Table of Contents

Key Research Papers

  1. Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA (2003). Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 26(12):3215–3218. — Khan 2003. — PubMed PMID: 14633804 — Expression of concern (Diabetes Care 2025: PubMed PMID: 40834253)
  2. Maierean SM, Serban MC, Sahebkar A, Ursoniu S, Serban A, Penson P, Banach M (2017). The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis. Journal of Clinical Lipidology 11(6):1393–1406. — PubMed PMID: 28887086
  3. de Moura SL, Gomes BGR, Guilarducci MJ, Coelho OGL, Guimarães NS, Gomes JMG (2025). Effects of cinnamon supplementation on metabolic biomarkers in individuals with type 2 diabetes: a systematic review and meta-analysis. Nutrition Reviews 83(2):249–279. — de Moura 2025. — PubMed PMID: 38917435
  4. Akilen R, Tsiami A, Devendra D, Robinson N (2010). Glycated haemoglobin and blood pressure-lowering effect of cinnamon in multi-ethnic Type 2 diabetic patients in the UK. Diabetic Medicine 27(10):1159–1167. — Akilen 2010 BP trial. — PubMed PMID: 20854384
  5. Hadi A, Campbell MS, Hassani B, Pourmasoumi M, Salehi-Sahlabadi A, Hosseini SA (2020). The effect of cinnamon supplementation on blood pressure in adults: A systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN 36:10–16. — Hadi 2020. — PubMed PMID: 32220351
  6. Zhang K, Li Y, Lin X, Daneshar M, Karamian F, Li M (2024). Effect of cinnamon supplementation on blood pressure, oxidative stress, and inflammatory biomarkers in adults: An umbrella review of the meta-analyses of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases 34(12):2659–2668. — Zhang 2024. — PubMed PMID: 39299867
  7. Jafari A, Mardani H, Faghfouri AH, AhmadianMoghaddam M, Musazadeh V, Alaghi A (2025). The effect of cinnamon supplementation on cardiovascular risk factors in adults: a GRADE assessed systematic review, dose-response and meta-analysis of randomized controlled trials. Journal of Health, Population and Nutrition 44(1):233. — Jafari 2025. — PubMed PMID: 40611215
  8. Mousavi SM, Rahmani J, Kord-Varkaneh H, Sheikhi A, Larijani B, Esmaillzadeh A (2020). Cinnamon supplementation positively affects obesity: A systematic review and dose-response meta-analysis of randomized controlled trials. Clinical Nutrition 39(1):123–133. — Mousavi 2020. — PubMed PMID: 30799194
  9. Mang B, Wolters M, Schmitt B, Kelb K, Lichtinghagen R, Stichtenoth DO, Hahn A (2006). Effects of a cinnamon extract on plasma glucose, HbA1c, and serum lipids in diabetes mellitus type 2. European Journal of Clinical Investigation 36(5):340–344. — Mang 2006. — PubMed PMID: 16634838
  10. Kim SY, Koo YK, Koo JY, Ngoc TM, Kang SS, Bae K, Kim YS, Yun-Choi HS (2010). Platelet anti-aggregation activities of compounds from Cinnamomum cassia. Journal of Medicinal Food 13(5):1069–1074. — Kim 2010 (laboratory study). — PubMed PMID: 20828311
  11. Azimi P, Ghiasvand R, Feizi A, Hosseinzadeh J, Bahreynian M, Hariri M, Khosravi-Boroujeni H (2016). Effect of cinnamon, cardamom, saffron and ginger consumption on blood pressure and a marker of endothelial function in patients with type 2 diabetes mellitus: A randomized controlled clinical trial. Blood Pressure 25(3):133–140. — Azimi 2016. — PubMed PMID: 26758574
  12. Ziegenfuss TN, Hofheins JE, Mendel RW, Landis J, Anderson RA (2006). Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. Journal of the International Society of Sports Nutrition 3:45–53. — Ziegenfuss 2006. — PubMed PMID: 18500972
  13. Roussel AM, Hininger I, Benaraba R, Ziegenfuss TN, Anderson RA (2009). Antioxidant effects of a cinnamon extract in people with impaired fasting glucose that are overweight or obese. Journal of the American College of Nutrition 28(1):16–21. — Roussel 2009 antioxidant. — PubMed PMID: 19571155
  14. Hlebowicz J et al. (2007). Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. American Journal of Clinical Nutrition 85(6):1552–1556. — Hlebowicz gastric emptying. — PubMed PMID: 17556692
  15. Ranasinghe P, Pigera S, Premakumara GA, Galappaththy P, Constantine GR, Katulanda P (2013). Medicinal properties of 'true' cinnamon (Cinnamomum zeylanicum): a systematic review. BMC Complementary and Alternative Medicine 13:275. — Ranasinghe Ceylon review. — PubMed PMID: 24148965

PubMed Topic Searches

  1. PubMed: Cinnamon cholesterol/triglycerides RCT
  2. PubMed: Cinnamon blood pressure
  3. PubMed: Cinnamaldehyde anti-platelet
  4. PubMed: Cinnamon endothelial function
  5. PubMed: Cinnamon metabolic syndrome / cardiovascular

Back to Table of Contents

Connections

Back to Table of Contents